• Molecular NameNevirapine
  • SynonymNEV; NVP
  • Weight265.316
  • Drugbank_IDDB00238
  • ACS_NO129618-40-2
  • Show 3D model
  • LogP (experiment)1.81
  • LogP (predicted, AB/LogP v2.0)2.59
  • pka2.8
  • LogD (pH=7, predicted)2.59
  • Solubility (experiment)0.007046 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.19
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.17
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA45.23
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability93.0
  • Protein binding60.0
  • Volume of distribution (VD)1.2 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized by CYP3A.
  • Half life45 h which decreases on multiple dosing to 20 to 30 h over a 2- to 4-week period.
  • ExcretionRenal: <6% (Parent drug), Biliary <5% (Parent drug)
  • Urinary Excretion<3
  • Clerance0.23~0.77 ml/min/kg (single dose) or 0.89 ml/min/kg (multiple dose)
  • ToxicitySymptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A